Antibacterial activity of statins: a comparative study of Atorvastatin, Simvastatin, and Rosuvastatin

Majed Masadeh1*, Nizar Mhaidat1, Karem Alzoubi1, Sayer Al-azzam1 and Ziad Alnasser2

Abstract

Background: Statins have several effects beyond their well-known antihyperlipidemic activity, which include immunomodulatory, antioxidative and anticoagulant effects. In this study, we have tested the possible antimicrobial activity of statins against a range of standard bacterial strains and bacterial clinical isolates.

Methods: Minimum inhibitory concentrations (MIC) values were evaluated and compared among three members of the statins drug (atorvastatin, simvastatin, and rosuvastatin).

Results: It was revealed that statins are able to induce variable degrees of antibacterial activity with atorvastatin, and simvastatin being the more potent than rosuvastatin. Methicillin-sensitive staphylococcus aureus (MSSA), methicillin-resistant staphylococcus aureus (MRSA), vancomycin-susceptible enterococci (VSE), vancomycin-resistant enterococcus (VRE), acinetobacter baumannii, staphylococcus epidermidis, and enterobacter aerogenes, were more sensitive to both atorvastatin, and simvastatin compared to rosuvastatin. On the other hand, escherichia coli, proteus mirabilis, and enterobacter cloacae were more sensitive to atorvastatin compared to both simvastatin and rosuvastatin. Furthermore, most clinical isolates were less sensitive to statins compared to their corresponding standard strains.

Conclusion: Our findings might raise the possibility of a potentially important antibacterial class effect for statins especially, atorvastatin and simvastatin.

Keywords: Antimicrobial activity, Statins, Atorvastatin, Simvastatin, Rosuvastatin

Background

Statins, also known as 3-hydroxy-3-methyl-glutaryl (HMG)-CoA reductase inhibitors, are a potent antihyperlipidemic drug group that is widely used for the treatment of hyperlipidemia. The HMG-CoA reductase is the enzyme responsible for the rate-limiting step in the cholesterol synthesis mevalonate pathway [1]. HMG-CoA inhibition results in a reduction of cholesterol synthesis and an increase in the synthesis of low-density-lipoprotein receptors. This, results in increased clearance of LDL cholesterol from the blood stream [2].

HMG-CoA reductase inhibitors are known to have effects beyond their lipid lowering effects, collectively known as pleiotropic effects [3]. These pleiotropic effects result in improvement of endothelial function, modulation of inflammatory responses and antioxidative effects, maintenance of plaque stability, and prevention of thrombus formation [4-6]. The area of pleiotropic effects of statins is promising and several such effects are being speculated.

Statins have also been investigated for their antibacterial action. In one study of the role of statins in community acquired pneumonia, [7] statins were shown to have immunomodulatory, and antioxidative actions, and a significant effect on the concentrations systemic cytokine [8-12]. Several animal studies [9,13-17] and observational studies in humans [18-22] have shown that individuals treated with statins are less prone to bacterial infection and present better outcomes. The antibacterial and anti-inflammatory effects of statins were investigated in a
meta-analysis, which suggested that statin use may be associated with useful outcomes in the treatment and prevention of different infections in recipients of solid-organ transplants [23,24]. This study aims to further investigate the antibacterial action of statins and identify their spectrum of action.

**Methods**

**Microbial culture and growth conditions**

Antibacterial activity of statins was evaluated against different reference bacteria including *E. coli* ATCC 35218, *Pseudomonas aeruginosa* ATCC 9027, MSSA ATCC 25213, MRSA ATCC 43300, *Streptococcus pneumoniae* ATCC 25923, VSE ATCC 19433, VRE ATCC 51299, *A. baumannii* ATCC 17978, *P. mirabilis* ATCC 12459, *Klebsiella pneumoniae* ATCC 13883, *Streptococcus pyogenes* ATCC 19615, *Haemophilus influenzae* ATCC 29247, *S. epidermidis* ATCC 12228, *E. aerogenes* ATCC 29751, *Citrobacter freundii* ATCC 8090, *E. cloacae* ATCC 13047, and against clinical isolates. Eighty clinical isolates were used in this study, comprising 14 different bacterial species. They were obtained from non-duplicate clinical specimens, including ear swab, throat swab, vaginal swab, sputum, urine, and blood culture, from the Microbiology Laboratory at King Abdullah University Hospital (KAUH) in north of Jordan, between April and September of 2010. The organisms were stored at −70°C in trypticase-soy broth and 20% glycerol (BBL Microbiology Systems, Md, USA). When ready for batch susceptibility testing, samples were thawed. To ensure purity and viability, samples were, then, passed 3 times. Minimum inhibitory concentrations (MICs) were determined in accordance with the Clinical and Laboratory Standards Institute (CLSI) [25].

**Determination of minimum inhibitory concentration (MIC)**

The MIC was determined by serial dilution method according to the National Committee for Clinical Laboratory Standards [26]. Briefly, statins were serially diluted, and added to plates containing molten BBL Muller-Hinton Gold II agar (BBL Microbiology Systems). Thereafter, plates were slightly cooled and dried. Then, using an a steer replicator, aliquots containing about $5 \times 10^4$ colony forming units per drop of different bacterial strains were placed in each plate. After an 18-hour incubation period at 37°C, plates were read. MIC was defined as the lowest concentration at which no growth, a faint haze or fewer than 3 discrete colonies were detected. Plates were read in duplicate, and the highest MIC value was recorded. The breakpoints indicated in the tables of the National Committee for CLSI [26] were used to determine susceptibility and resistance.

**Chemicals**

Simvastatin atorvastatin and Rosuvastatin were a generous gift from Advanced Pharmaceutical Industries (Amman, Jordan). Drugs (simvastatin, atorvastatin and rosuvastatin) were dissolved in DMSO to a stock concentration of 1 mg/ml, and they were used for MIC determination. All drugs were used as raw materials. DMSO was used to help in dissolving the drugs used. As DMSO is known for possessing no antibacterial activity of its own, DMSO/no statin served as a negative control.

**Statistics**

Analysis was performed using GraphPad Prism software (version 4.0, GraphPad software, LA jolle, CA). One-way ANOVA followed by Tukey’s post-test were used to determine if there was any statistically significant difference. *P*-values < 0.05 was considered significant.

**Results**

The antibacterial activity of atorvastatin, simvastatin, and rosuvastatin were investigated against 16 standard bacterial strains. Results shown in Table 1 revealed that statins are able to induce variable degrees of antibacterial activity, where atorvastatin and simvastatin are the most potent. MSSA, MRSA, VSE, VRE, *A. baumannii*, *S. epidermidis*, and *E. aerogenes*, were more sensitive to

| Bacteria                  | Rosuvastatin | Atorvastatin | Simvastatin |
|---------------------------|-------------|--------------|-------------|
| *E. coli* ATCC 35218      | 104.17 ± 36.08 | 26.04 ± 9.02* | 52.08 ± 18.04 |
| *P. aeruginosa* ATCC 9027 | 166.67 ± 72.16 | 83.33 ± 36.08 | 166.67 ± 72.16 |
| MSSA ATCC 25213           | 208.33 ± 72.16 | 41.67 ± 18.04* | 26.04 ± 9.02* |
| MRSA ATCC 43300           | 500 ± 0.00   | 83.33 ± 36.08* | 166.67 ± 72.16* |
| *S. pneumoniae* ATCC 25923| 333.33 ± 144.33 | 104.17 ± 36.08 | 166.67 ± 72.16 |
| VSE ATCC 19433            | 333.33 ± 144.33 | 83.33 ± 36.08* | 52.08 ± 18.04* |
| VRE ATCC 51299            | 500 ± 0.00   | 166.67 ± 72.16* | 104.17 ± 36.08* |
| *A. baumannii* ATCC 17978 | 333.33 ± 144.33 | 15.62 ± 0.00* | 104.17 ± 36.08* |
| *P. mirabilis* ATCC 12459 | 250 ± 0.00   | 62.5 ± 0.00*   | 166.67 ± 72.16 |
| *K. pneumoniae* ATCC 13883| 333.33 ± 144.33 | 166.67 ± 72.16 | 166.67 ± 72.16 |
| *S. pyogenes* ATCC 19615   | 166.67 ± 72.16 | 83.33 ± 36.08 | 62.5 ± 0.00 |
| *H. influenzae* ATCC 29247| 166.67 ± 72.16 | 83.33 ± 36.08* | 52.08 ± 18.04 |
| *S. epidermidis* ATCC 12228| 166.67 ± 72.16 | 20.83 ± 9.02* | 26.04 ± 9.02* |
| *E. aerogenes* ATCC 29751  | 104.17 ± 36.08 | 15.62 ± 0.00* | 26.04 ± 9.02* |
| *C. freundii* ATCC 8090   | 166.67 ± 72.16 | 83.33 ± 36.08 | 52.08 ± 18.04 |
| *E. cloacae* ATCC 13047    | 166.67 ± 72.16 | 41.67 ± 18.04* | 62.5 ± 0.00 |

* Indicates significant difference from rosuvastatin group.

DMSO is used to help in dissolving the drugs used. As DMSO is known for possessing no antibacterial activity of its own, DMSO/no statin served as a negative control.
both atorvastatin, and simvastatin compared to rosuvastatin ($P < 0.05$). On the other hand, E. coli, P. mirabilis, and E. cloacae were more sensitive to atorvastatin compared to both simvastatin and rosuvastatin ($P < 0.05$).

We next studied the antibacterial activity of statins against 16 clinical isolates of bacteria by measuring MIC values. Most clinical isolates were less sensitive to statins compared to their corresponding standard strains (Table 2). In addition, when compared for their antibacterial activity atorvastatin and simvastatin were significantly more potent compared to Rosuvastatin. For example, P. aeruginosa, MSSA, MRSA, S. pneumoniae, VRE, A. baumannii, H. influenza, S. epidermidis, E. aerogenes, C. freundii, and E. cloacae were more sensitive to atorvastatin and simvastatin compared to rosuvastatin ($P < 0.05$, Table 2). Additionally, VSE and VRE isolates were significantly more sensitive to atorvastatin compared to simvastatin ($P < 0.05$, Table 2).

### Discussion

The emergence of drug resistance with patient’s poor compliance, drugs adverse effects and the higher cost of therapy combinations, indicates a strong need for a therapy regimens with similar or higher antibiotics beneficial properties but with better adverse effects profiles. Results of the current study suggest a class effect antibacterial activity for statins, and indicate the superiority of the antibacterial activity of atorvastatin and simvastatin against several standard bacterial strains and clinical isolates as compared to rosuvastatin.

Statins were demonstrated to have pharmacological actions beyond their antihyperlipidemic properties including immunomodulatory, antioxidative and anticoagulant effects. A recent study indicated a direct antimicrobial effect of simvastatin and to a lesser extent fluvastatin against MSSA and MRSA [27]. Another study showed the antibacterial effect of atorvastatin and rosuvastatin in Gram + and Gram− bacteria [28]. Results of the present study extend those of previous studies to include more agents of the statins family and test these agents against a wide range of standard bacterial strains and clinical isolates.

A very recent study has reported MIC values for simvastatin against S. pneumoniae and M. catarrhalis that are similar to the ones reported in this study [29]. These MIC values reflect concentrations of statins that are higher than regular concentrations detected in human blood during statins therapy [30]. However, since multiple dose statins are known for their favorable effect on the course of bacterial infections [18-22], it is possible that statins undergoes accumulation at target human tissues upon multiple dosing, or there could a formation of relevant breakdown products in vivo. Alternatively, statins could aid the action of other antibacterial agent during the treatment of infections in human through their reported pleiotropic actions [31-33]. Statins induce their antihyperlipidemic, via inhibition of HMG-CoA reductase. In bacterial cells, HMG-CoA reductase is essential, where it is required for the biosynthesis of isoprenes [34]. However, bacterial HMG-CoA reductase is of a different structural class with an affinity for statins that is 10 000 times weaker than the enzyme found in eukaryotes [34]. Thus, it is unlikely that antibacterial activity of statins can be attributed to the known mechanism of action (i.e. inhibition of HMG-CoA reductase). Other possible mechanisms could be related to the pleiotropic properties of statins. For example, multiple statins including atorvastatin and simvastatin, were shown to be cytopathic, to suppress cells growth, and to promote apoptosis [31-33]. It is possible that the currently reported antibacterial activity of statins is related to such effects.

Results of the current study showed the superiority of the antibacterial effects of atorvastatin or simvastatin to that of rosuvastatin. Previous studies have reported distinct effects, other than the antibacterial activity, for atorvastatin and simvastatin, compared to other members of statins [35,36]. Additionally, our results show that atorvastatin was superior to simvastatin against VSE and VRE clinical isolates. These distinct effects could also be related to the differences in chemical structure of statins.

### Table 2 Minimum inhibitory concentrations (MIC; μg/mL) of different statins against different clinical isolates

| Clinical Isolate | Rosuvastatin | Atorvastatin | Simvastatin |
|------------------|--------------|--------------|-------------|
| E. coli Isolates | 125.00 ± 16.14 | 100.00 ± 33.75 | 112.5 ± 30.19 |
| P. aeruginosa Isolates | 291.67 ± 39.53 | 95.83 ± 22.09* | 120.83 ± 32.27* |
| MSSA Isolates | 341.67 ± 20.84 | 52.08 ± 11.04* | 60.42 ± 12.76* |
| MRSA Isolates | 500.00 ± 0.00 | 108.33 ± 27.36* | 116.67 ± 30.19* |
| S. pneumoniae Isolates | 416.67 ± 0.00 | 229.17 ± 60.38* | 291.67 ± 39.53* |
| VSE Isolates | 333.33 ± 0.00 | 95.83 ± 22.09* | 291.67 ± 39.53* |
| VRE Isolates | 500.00 ± 0.00 | 216.67 ± 32.27* | 291.67 ± 39.53* |
| A. baumannii Isolates | 300.00 ± 79.05 | 21.87 ± 4.94* | 32.29 ± 6.38* |
| P. mirabilis Isolates | 191.67 ± 32.27 | 127.08 ± 25.51 | 158.33 ± 32.27 |
| K. pneumoniae Isolates | 258.33 ± 64.55 | 216.67 ± 51.03 | 241.67 ± 60.38 |
| S. pyogenes Isolates | 275.00 ± 72.17 | 133.33 ± 36.08* | 145.83 ± 32.27 |
| H. influenzae Isolates | 366.67 ± 0.00 | 104.17 ± 36.08* | 145.83 ± 32.27* |
| S. epidermidis Isolates | 233.33 ± 39.52 | 19.78 ± 4.94* | 35.41 ± 4.94* |
| E. aerogenes Isolates | 183.33 ± 0.00 | 19.78 ± 4.94* | 33.33 ± 4.94* |
| C. freundii Isolates | 333.33 ± 79.06 | 108.33 ± 27.36* | 133.33 ± 39.58* |
| E. cloacae Isolates | 316.67 ± 64.55 | 113.54 ± 27.06* | 143.75 ± 36.97* |

MICs were determined using serial dilution method according to the procedures National Committee for Clinical Laboratory Standards. * indicates significant difference from rosuvastatin group. # indicates significant difference from atorvastatin group.
among statins. For example, simvastatin is naturally product of fungal fermentation, whereas atorvastatin is a chemically synthesized derivative. Additionally, statins differ in their lipids affinity, thus, they could have different intrinsic activities. However, these points need more study, and could be a matter of future work.

Conclusion
In summary, results of the current study raise the possibility of a potentially important class effect and future studies are recommended to elucidate mechanism(s) by which atorvastatin and simvastatin are inducing their antibacterial effects.

Competing interests
The authors declare that they have no competing interests.

Acknowledgment
We would like to acknowledge Jordan University of Science & Technology, Irbid, Jordan for the financial support (grant number 73–2006 & 226–2009).

Author details
1. Faculty of Pharmacy, Jordan University of Science & Technology, Irbid 22110, Jordan. 2. Faculty of Medicine, Jordan University of Science & Technology, Irbid 22110, Jordan.

Authors’ contributions
MM carried out MIC determination studies, and participated in drafting the manuscript. NM participated in MIC determination studies, and study design, and helped in drafting the manuscript. KA participated in the design of the manuscript. MM carried out MIC determination studies, and participated in drafting the manuscript. All authors conceived of the study, and participated in its design and coordination and study, performed the statistical analysis, and drafted the manuscript. SA read and approved the final manuscript.

Received: 19 February 2012 Accepted: 7 May 2012
Published: 7 May 2012

References
1. Chatzizisis YS, Koskinas KC, Misirli G, Vaklavas C, Hatzitolios A, Giannoglou GD: Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf. 2010, 33(11):171–187.
2. Schneck DW, Knopp RH, Ballantyne CM, McPherson R, Chitra RR, Simonson SG: Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol. 2005, 91(1):43–47.
3. Kostapanos MS, Milionis HJ, Elisaf MS: An overview of the extra-lipid effects of rosuvastatin. J Cardiovasc Pharmacol Ther. 2008, 13:157–174.
4. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Frucht JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Woloki K, Goormastic M, Tuzcu EM: Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006, 295(15):1556–1565.
5. Furberg CD: Natural statins and stroke risk. Circulation. 1999, 99:185–188.
6. Ridker PM, Danielson E, Fonseca FA, Gent J, Gotto AM Jr, Kastelein JJ, Koening W, Libby P, Lerenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RR: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008, 359:2195–2207.
7. Vlasus D, Garcia-Vidal C, Gudul F, Carratala J: Statins for community-acquired pneumonia: current state of the science. Eur J Clin Microbiol Infect Dis. 2010, 29:143–152.
8. Bielinska A, Gluzko P: Statins—are they potentially useful in rheumatology? Pol Arch Med Wewn. 2007, 117:420–425.
9. Undas A, Brummel-Ziedins KE, Mann KG: Statins and blood coagulation. Antithromb Thromb Vasc Biol. 2005, 25:287–294.
10. Novack V, Eisinger M, Fenikel A, Terblanche M, Adhikari NK, Doudevan A, Aronchay D, Almog Y: The effects of statin therapy on inflammatory cytokines in patients with bacterial infections: a randomized double-blind placebo controlled clinical trial. Intensive Care Med. 2009, 35:1255–1260.
11. Liao, JK; Laufs U: Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005, 45:89–118.
12. Terblanche M, Almog Y, Rosenson RS, Smith TS, Hackag DM: Statins and sepsis: multiple modifications at multiple levels. Lancet Infect Dis. 2007, 7:358–368.
13. Merx MW, Liehn EA, Janssens U, Lutticken R, Schrader J, Hannah P, Weber C: HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation. 2004, 109:2560–2565.
14. Merx MW, Liehn EA, Graf J, van de Sandt A, Schaltenbrand M, Schrader J, Hannah P, Weber C: Statin treatment after onset of sepsis in a murine model improves survival. Circulation. 2005, 112:117–124.
15. Chaudhry MZ, Wang JH, Blankson S, Redmond HP: Statin (cerivastatin) protects mice against sepsis-related death via reduced proinflammatory cytokines and enhanced bacterial clearance. Surg Infect (Larchmt). 2008, 9:183–194.
16. Souza Neto J, Araujo Filho J, Rego AC, Domincia VC, Azevedo IM, Egito ES, Brandao-Neto J, Medeiros AC: Effects of simvastatin in abdominal sepsis in rats. Acta Cir Bras. 2006, 21(Suppl 4):12–18.
17. Chen CH, Lee RP, Wu WT, Liao KW, Hsu N, Hsu BG: Fluvasatin ameliorates endotoxin induced multiple organ failure in conscious rats. Resuscitation. 2007, 74:166–174.
18. Hardack DM, Mamdani M, Li P, Redelmeier DA: Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet. 2006, 367:413–418.
19. Almog Y, Shefer A, Novack V, Maimon N, Barski L, Eizinger M, Friger M, Zeller L, Danon A: Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation. 2004, 110:880–885.
20. Liappis AP, Kan V, Rochester CG, Simon GL: The effect of statins on mortality in patients with bacteremia. Clin Infect Dis. 2001, 33:1532–1537.
21. Thomsen RW, Hundborg HH, Johnsen SP, Pedersen L, Sorensen HT, Schonheyder HC, Lervang HH: Statin use and mortality within 180 days after bacteremia: a population-based cohort study. Crit Care Med. 2006, 34:1080–1086.
22. Kruger P, Fitzsimmons K, Cook D, Jones M, Nimmor G: Statin therapy is associated with fewer deaths in patients with bacteraemia. Intensive Care Med. 2006, 32:75–79.
23. Sun HY, Singh N: Antimicrobial and immunomodulatory attributes of statins: relevance in solid-organ transplant recipients. Clin Infect Dis. 2009, 48:745–755.
24. Tleyjeh IM, Kashour T, Hakim FA, Zimmerman VA, Erwin PJ, Sutton AJ, Ibrahim T: Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch Intern Med. 2009, 169:1658–1667.
25. Clinical and Laboratory Standards Institute (CLSI): Performance standards for antimicrobial susceptibility testing. M100-S20. Available from [http://www.clsi.org/source/orders/free/m100-s20.pdf]. Accessed 14 September 2011.
26. Jerwood S, Cohen J: Unexpected antimicrobial effect of statins. J Antimicrob Chemother. 2006, 61:362–364.
27. Welsh AM, Kruger P, Faoagali J: Antimicrobial action of atorvastatin and rosuvastatin. Pathology. 2009, 41:389–691.
28. Bergman P, Linde C, Putsep K, Polhanka A, Normark S, Henriquez-Normark B, Andersson J, Bjerkhjem-Bergman L: Studies on the antibacterial effects of statins—in vitro and in vivo. PLoS One 2011, 6:e24394.
29. Bjerkhjem-Bergman L, Lindh JD, Bergman P: What is a relevant statin concentration in cell experiments claiming pleiotropic effects? Br J Clin Pharmacol. 2011, 72:164–165.
30. Yamazaki H, Suzuki M, Aoki T, Morikawa S, Maejima T, Sato F, Sawanobori K, Hanrath P, Weber C, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Hanrath P, Weber C: Statin treatment after onset of sepsis in a murine model improves survival. Circulation. 2005, 112:117–124.
31. Yamazaki H, Suzuki M, Aoki T, Morikawa S, Maejima T, Sato F, Sawanobori K, Hanrath P, Weber C: Statin treatment after onset of sepsis in a murine model improves survival. Circulation. 2005, 112:117–124.
32. Muck AO, Seeger H, Wallwiener D: Class-specific pro-apoptotic effect of statins on human vascular endothelial cells. Z Kardiol. 2004, 93:319–402.
33. Tapia-Perez JH, Kirches E, Mawrin C, Firsching R, Schneider T: Cytotoxic effect of different statins and thiazolidinediones on malignant glioma cells. Cancer Chemother Pharmacol 2011, 67:1193–1201.

34. Friesen JA, Rodwell VW: The 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductases. Genome Biol 2004, 5:248.

35. Tesfamariam B, Frohlich BH, Gregg RE: Differential effects of pravastatin, simvastatin, and atorvastatin on Ca2+ release and vascular reactivity. J Cardiovasc Pharmacol 1999, 34:95–101.

36. Ishikawa M, Okajima F, Inoue N, Motomura K, Kato T, Takahashi A, Oikawa S, Yamada N, Shimano H: Distinct effects of pravastatin, atorvastatin, and simvastatin on insulin secretion from a beta-cell line, MIN6 cells. J Atheroscler Thromb 2006, 13:329–335.

doi:10.1186/1476-0711-11-13
Cite this article as: Masadeh et al: Antibacterial activity of statins: a comparative study of Atorvastatin, Simvastatin, and Rosuvastatin. Annals of Clinical Microbiology and Antimicrobials 2012 11:13.